Last edition
News about "GLP-1 therapies "
The rise of GLP-1 therapies has transformed diabetes and obesity treatment. Following semaglutide patent expiry in India in March 2026, multiple companies entered the market simultaneously. Pharma Industrial India spoke with industry leaders about the opportunities, challenges, and future of this rapidly evolving therapeutic segment.
GLP-1 Therapies | 26/06/2026 | By Akanki
Aptar Pharma Files Patents, Reports Positive Preclinical Data for GLP-1 Nasal and Pulmonary Delivery
Aptar Pharma announced new patent applications and positive preclinical data supporting intranasal and pulmonary GLP-1 delivery, expanding its capabilities in inhaled and intranasal biologic drug delivery.
GLP-1 Therapies | 29/05/2026 | By News Bureau | 125
Biohaven Completes Enrollment in Phase II Trial of Taldefgrobep for Obesity
Biohaven finishes enrollment in Phase II study of taldefgrobep, a novel therapy targeting fat loss and muscle gain, with topline data expected in the second half of 2026.
GLP-1 Therapies | 21/03/2026 | By News Bureau | 295
TempraMed Technologies Inks Distribution Agreement with Guri
The partnership marks TempraMed’s entry into a broader global rollout, with the Guri agreement serving as the first step in a series of regional distribution deals planned across Europe, the Middle East, North America, and Asia.
GLP-1 Therapies | 28/11/2025 | By Dineshwori | 223
BioNxt Begins Lab-Scale ODF Development After Receiving Semaglutide API
BioNxt Solutions has received the Semaglutide active pharmaceutical ingredient (API), enabling the initiation of laboratory-scale formulation and testing of its oral dissolvable film (ODF) delivery system.
GLP-1 Therapies | 03/09/2025 | By Dineshwori | 501
Aardvark Therapeutics Secures USD 85 Million Oversubscribed Series C Financing
Aardvark Therapeutics, Inc. has received an USD 85 million oversubscribed Series C financing led by Decheng Capital.
GLP-1 Therapies | 10/05/2024 | By Aishwarya | 501
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy